Overview

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Arvinas Estrogen Receptor, Inc.
Collaborator:
Pfizer
Treatments:
Everolimus